Abstract 1040O
Background
Immunotherapy with ipilimumab and nivolumab has response rates of 45-55%, but 50% of patients (pts) suffer grade 3-5 immune-related adverse events. High serum IL-6 is associated with a poor outcome with checkpoint inhibition and with short survival in many cancers. Tocilizumab is a humanized IL-6 receptor blocking antibody approved for several arthritides and cytokine release syndrome. In anecdotal cases it reverses steroid-resistant colitis and other immune toxicities. To assess if tocilizumab could reduce toxicity and/or augment efficacy of checkpoint inhibition, a phase II trial of ipilimumab, nivolumab and tocilizumab was performed. Results from the first stage of the trial are reported.
Methods
In this Simon two-stage design phase II study, eligible pts had untreated unresectable/metastatic melanoma. Adjuvant therapy was permitted. Ipilimumumab at 1 mg/kg, and nivolumab at 3 mg/kg were administered intravenously (IV) every 3 weeks (wks), 4 times during induction, then nivolumab maintenance is given for up to 2 years. Tocilizumab was given at 4 mg/kg every 6 wks IV during the first 24 wks. In stage 1 >/= 11 responses in 18 were required and/or less than 6 pts with grade 3-5 irAEs to proceed to stage 2 to total 67 pts.
Results
Twenty-eight pts have started therapy including 14 men and 14 women with a median age of 67. Twenty had ECOG PS 1, and 8 PS 0. Twenty-four pts had stage IV and 4 stage IIIc/d disease. There were 5 grade 3-4 irAEs with one each with enteritis, colitis and nephritis and two with trasaminitis. At 6 months of median follow up, there are 14 RECIST responses of 20 pts (70% ORR) with at least one evaluation at week 12. Two pts are stable at 18 weeks. No responder or stable pts have progressed. Four pts progressed, and two died. Correlative marker studies by serum Luminex assay showed that higher levels of baseline TNF-alpha were associated with grade 3-4 toxicity, and elevated IL-6/IL-8 and C5a at week 7 were associated with progression.
Conclusions
Flipped dose IPI/NIVO with TOCI has promising anti-tumor activity with a favorable toxicity profile. Incidence of grade 3/4 irAEs was 25%. High baseline TNF-a was associated with grade 3/4 irAEs, and elevated week 7 IL-6/IL-8/C5a were associated with progression. Further correlative studies will be presented.
Clinical trial identification
NCT03999749.
Editorial acknowledgement
Legal entity responsible for the study
NYU Grossman School of Medicine.
Funding
Bristol-Myers Squibb.
Disclosure
J.S. Weber: Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Genentech. O. Hamid: Financial Interests, Personal and Institutional, Invited Speaker: BMS; Financial Interests, Personal and Institutional, Invited Speaker: Genentech. J. Mehnert: Financial Interests, Personal and Institutional, Advisory Board: BMS. F.S. Hodi: Financial Interests, Personal and Institutional, Advisory Board: BMS; Financial Interests, Personal and Institutional, Advisory Board: Genentech. E. Buchbinder: Financial Interests, Personal and Institutional, Advisory Board: BMS; Financial Interests, Personal and Institutional, Advisory Board: Genentech. J. Goldberg: Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Advisory Board: Genentech. R. Sullivan: Financial Interests, Personal and Institutional, Advisory Board: BMS; Financial Interests, Personal and Institutional, Advisory Board: Genentech. M. Faries: Financial Interests, Personal and Institutional, Advisory Board: BMS; Financial Interests, Personal and Institutional, Advisory Board: Genentech. I. Mehmi: Financial Interests, Personal and Institutional, Advisory Board: BMS; Financial Interests, Personal and Institutional, Advisory Board: Genentech. All other authors have declared no conflicts of interest.
Resources from the same session
1036O - Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047
Presenter: F. Stephen Hodi
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1037O - MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)
Presenter: Helen Gogas
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 1036O and 1040O
Presenter: Olivier Michielin
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Olivier Michielin
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Slides
Webcast
Invited Discussant 1037O
Presenter: James Larkin
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: James Larkin
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Slides
Webcast